Daptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococci

International Journal of Antimicrobial Agents

Volumn 44, Issue 5, 2014, Pages 387-395

  Munita, Jose M ^a,b   Murray, Barbara E ^a   Arias, Cesar A ^a,b,c  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSIDAD DEL DESARROLLO   (Chile)

^c UNIVERSIDAD EL BOSQUE   (Colombia)

Author keywords

Daptomycin; Enterococcal bacteraemia; Enterococci; VRE

Indexed keywords

AMINOGLYCOSIDE; AMPICILLIN; BETA LACTAM ANTIBIOTIC; CEFTAROLINE; CEFTRIAXONE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; GENTAMICIN; LINEZOLID; RIFAMPICIN; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTEREMIA; BACTERIAL CLEARANCE; BACTERIAL ENDOCARDITIS; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; COMBINATION CHEMOTHERAPY; DISEASE MODEL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERANCE; DRUG TREATMENT FAILURE; ENTEROCOCCAL BACTEREMIA; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LENGTH OF STAY; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; RECURRENT INFECTION; REVIEW; VANCOMYCIN RESISTANT ENTEROCOCCUS; ANIMAL; GRAM-POSITIVE BACTERIAL INFECTIONS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTEREMIA; DAPTOMYCIN; DISEASE MODELS, ANIMAL; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; TREATMENT OUTCOME; VANCOMYCIN-RESISTANT ENTEROCOCCI;

EID: 84908448459     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2014.08.002     Document Type: Review

References (76)

1. A.I. Hidron, J.R. Edwards, J. Patel, T.C. Horan, D.M. Sievert, and D.A. Pollock National Healthcare Safety Network Team; Participating National Healthcare Safety Network Facilities. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007 Infect Control Hosp Epidemiol 29 2008 996 1011
2. C.A. Arias, and B.E. Murray The rise of the Enterococcus: beyond vancomycin resistance Nat Rev Microbiol 10 2012 266 278
3. J.E. Geraci, and W.J. Martin Antibiotic therapy of bacterial endocarditis. VI. Subacute enterococcal endocarditis: clinical, pathologic and therapeutic consideration of 33 cases Circulation 10 1954 173 194
4. W.C. Robbins, and R. Tompsett Treatment of enterococcal endocarditis and bacteremia: results of combined therapy with penicillin and streptomycin Am J Med 10 1951 278 299
5. E. Jawetz, J.B. Gunnison, and V.R. Coleman The combined action of penicillin with streptomycin or chloromycetin on enterococci in vitro Science 111 1950 254 256
6. L.M. Baddour, W.R. Wilson, A.S. Bayer, V.G. Fowler Jr., A.F. Bolger, and M.E. Levison Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease; Council on Cardiovascular Disease in the Young; Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia; American Heart Association; Infectious Diseases Society of America. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America Circulation 111 2005 e394 e434
7. C.A. Arias, G.A. Contreras, and B.E. Murray Management of multidrug-resistant enterococcal infections Clin Microbiol Infect 16 2010 555 562
8. C.A. Arias, R.E. Mendes, M.G. Stilwell, R.N. Jones, and B.E. Murray Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections Clin Infect Dis 54 2012 S233 S238
9. H.S. Sader, G.J. Moet, D.J. Farrell, and R.N. Jones Antimicrobial susceptibility of daptomycin and comparator agents tested against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: trend analysis of a 6-year period in US medical centers (2005-2010) Diagn Microbiol Infect Dis 70 2011 412 416
10. European Centre for Disease Prevention and Control. Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals 2011-2012. Stockholm, Sweden: ECDC; 2013.
11. C.A. DiazGranados, S.M. Zimmer, M. Klein, and J.A. Jernigan Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis Clin Infect Dis 41 2005 327 333
12. P. Prasad, J. Sun, R.L. Danner, and C. Natanson Excess deaths associated with tigecycline after approval based on noninferiority trials Clin Infect Dis 54 2012 1699 1709
13. R. Cantón, P. Ruiz-Garbajosa, R.L. Chaves, and A.P. Johnson A potential role for daptomycin in enterococcal infections: what is the evidence? J Antimicrob Chemother 65 2010 1126 1136
14. S.E. Cosgrove, and G.R. Corey A balancing act: microbe versus muscle Clin Infect Dis 49 2009 181 183
15. European Medicines Agency. Cubicin (daptomycin). 〈 http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000637/human-med-000730.jsp&mid=WC0b01ac058001d124 ⌠[accessed 17.07.14].
16. T. Zhang, J.K. Muraih, N. Tishbi, J. Herskowitz, R.L. Victor, and J. Silverman Cardiolipin prevents membrane translocation and permeabilization by daptomycin J Biol Chem 289 2014 11584 11591
17. J. Pogliano, N. Pogliano, and J.A. Silverman Daptomycin-mediated reorganization of membrane architecture causes mislocalization of essential cell division proteins J Bacteriol 194 2012 4494 4504
18. H.S. Sader, D.J. Farrell, R.K. Flamm, and R.N. Jones Daptomycin activity tested against 164 457 bacterial isolates from hospitalised patients: summary of 8 years of a Worldwide Surveillance Programme (2005-2012) Int J Antimicrob Agents 43 2014 465 469
19. H.S. Sader, R.K. Flamm, and R.N. Jones Antimicrobial activity of daptomycin tested against Gram-positive pathogens collected in Europe, Latin America, and selected countries in the Asia-Pacific Region (2011) Diagn Microbiol Infect Dis 75 2013 417 422
20. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement. Document M100-S21. Wayne, PA: CLSI; 2011.
21. I.I. Raad, H.A. Hanna, M. Boktour, G. Chaiban, R.Y. Hachem, and T. Dvorak Vancomycin-resistant Enterococcus faecium: catheter colonization, esp gene, and decreased susceptibility to antibiotics in biofilm Antimicrob Agents Chemother 49 2005 5046 5050
22. I. Raad, H. Hanna, Y. Jiang, T. Dvorak, R. Reitzel, and G. Chaiban Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm Antimicrob Agents Chemother 51 2007 1656 1660
23. F. Caron, M.D. Kitzis, L. Gutmann, A.C. Cremieux, B. Maziere, and J.M. Vallois Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium Antimicrob Agents Chemother 36 1992 2611 2616
24. A.C. Cremieux, B. Maziere, J.M. Vallois, M. Ottaviani, A. Azancot, and H. Raffoul Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography J Infect Dis 159 1989 938 944
25. C. Tascini, A. Di Paolo, R. Poletti, S. Flammini, M. Emdin, and I. Ciullo Daptomycin concentrations in valve tissue and vegetation in patients with bacterial endocarditis Antimicrob Agents Chemother 57 2013 601 602
26. R. Cha, and M.J. Rybak Daptomycin against multiple drug-resistant staphylococcus and enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations Diagn Microbiol Infect Dis 47 2003 539 546
27. R.L. Akins, and M.J. Rybak Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations Antimicrob Agents Chemother 45 2001 454 459
28. A.D. Hall, M.E. Steed, C.A. Arias, B.E. Murray, and M.J. Rybak Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations Antimicrob Agents Chemother 56 2012 3174 3180
29. M.C. Ramos, M.L. Grayson, G.M. Eliopoulos, and A.S. Bayer Comparison of daptomycin, vancomycin, and ampicillin-gentamicin for treatment of experimental endocarditis caused by penicillin-resistant enterococci Antimicrob Agents Chemother 36 1992 1864 1869
30. R.G. Hindes, S.H. Willey, G.M. Eliopoulos, L.B. Rice, C.T. Eliopoulos, and B.E. Murray Treatment of experimental endocarditis caused by a β-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin Antimicrob Agents Chemother 33 1989 1019 1022
31. J. Vouillamoz, P. Moreillon, M. Giddey, and J.M. Entenza Efficacy of daptomycin in the treatment of experimental endocarditis due to susceptible and multidrug-resistant enterococci J Antimicrob Chemother 58 2006 1208 1214
32. S. Kennedy, and H.F. Chambers Daptomycin (LY146032) for prevention and treatment of experimental aortic valve endocarditis in rabbits Antimicrob Agents Chemother 33 1989 1522 1525
33. J.A. Segreti, C.W. Crank, and M.S. Finney Daptomycin for the treatment of Gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients Pharmacotherapy 26 2006 347 352
34. J.C. Gallagher, M.E. Pérez, E.A. Marino, L.G. LoCastro, L.A. Abrardo, and C. MacDougall Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients Pharmacotherapy 29 2009 792 799
35. J.F. Mohr, L.V. Friedrich, S. Yankelev, and K.C. Lamp Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE) Int J Antimicrob Agents 33 2009 543 548
36. G. Sakoulas, Y. Golan, K.C. Lamp, L.V. Friedrich, and R. Russo Daptomycin in the treatment of bacteremia Am J Med 120 2007 S21 S27
37. K.V. Rolston, D. Besece, K.C. Lamp, M. Yoon, S.A. McConnell, and P. White Daptomycin use in neutropenic patients with documented Gram-positive infections Support Care Cancer 22 2014 7 14
38. D.D. Poutsiaka, S. Skiffington, K.B. Miller, S. Hadley, and D.R. Snydman Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients J Infect 54 2007 567 571
39. J.E. Brown, C. Fominaya, K.J. Christensen, S.A. McConnell, and K.C. Lamp Daptomycin experience in critical care patients: results from a registry Ann Pharmacother 46 2012 495 502
40. V. Mave, J. García-Díaz, T. Islam, and R. Hasbun Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid? J Antimicrob Chemother 64 2009 175 180
41. J.A. McKinnell, M. Patel, R.M. Shirley, D.F. Kunz, S.A. Moser, and J.W. Baddley Observational study of the epidemiology and outcomes of VRE bacteraemia treated with newer antimicrobial agents Epidemiol Infect 139 2011 1342 1350
42. C.W. Crank, M.H. Scheetz, B. Brielmaier, W.E. Rose, G.P. Patel, and D.J. Ritchie Comparison of outcomes from daptomycin or linezolid treatment for vancomycin-resistant enterococcal bloodstream infection: a retrospective, multicenter, cohort study Clin Ther 32 2010 1713 1719
43. J.D. Twilla, C.K. Finch, J.B. Usery, M.S. Gelfand, J.Q. Hudson, and J.E. Broyles Vancomycin-resistant Enterococcus bacteremia: an evaluation of treatment with linezolid or daptomycin J Hosp Med 7 2012 243 248
44. S. Kraft, E. Mackler, P. Schlickman, K. Welch, and D.D. DePestel Outcomes of therapy: vancomycin-resistant enterococcal bacteremia in hematology and bone marrow transplant patients Support Care Cancer 19 2011 1969 1974
45. K. Hayakawa, E.T. Martin, U.M. Gudur, D. Marchaim, D. Dalle, and K. Alshabani The impact of different antimicrobial therapies on clinical and fiscal outcomes of patients with bacteremia due to vancomycin-resistant enterococci Antimicrob Agents Chemother 58 2014 3968 3975
46. D.W. Whang, L.G. Miller, N.M. Partain, and J.A. McKinnell Systematic review and meta-analysis of linezolid and daptomycin for treatment of vancomycin-resistant enterococcal bloodstream infections Antimicrob Agents Chemother 57 2013 5013 5018
47. E.P. Balli, C.A. Venetis, and S. Miyakis Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia Antimicrob Agents Chemother 58 2014 734 739
48. D.P. Levine, and K.C. Lamp Daptomycin in the treatment of patients with infective endocarditis: experience from a registry Am J Med 120 2007 S28 S33
49. J.M. Munita, C.A. Arias, and B.E. Murray Enterococcal endocarditis: can we win the war? Curr Infect Dis Rep 14 2012 339 349
50. I. Cerón, P. Muñoz, M. Marín, A. Segado, J. Roda, and M. Valerio Efficacy of daptomycin in the treatment of enterococcal endocarditis: a 5 year comparison with conventional therapy J Antimicrob Chemother 69 2014 1669 1674
51. R. Kullar, A.M. Casapao, S.L. Davis, D.P. Levine, J.J. Zhao, and C.W. Crank A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis J Antimicrob Chemother 68 2013 2921 2926
52. M. Carugati, A.S. Bayer, J.M. Miró, L.P. Park, A.C. Guimarães, and A. Skoutelis High-dose daptomycin therapy for left-sided infective endocarditis: a prospective study from the International Collaboration on Endocarditis Antimicrob Agents Chemother 57 2013 6213 6222
53. L.S. Munoz-Price, K. Lolans, and J.P. Quinn Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection Clin Infect Dis 41 2005 565 566
54. J.S. Lewis 2nd, A. Owens, J. Cadena, K. Sabol, J.E. Patterson, and J.H. Jorgensen Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy Antimicrob Agents Chemother 94 2005 1664 1665
55. T. Kelesidis, R. Humphries, D.Z. Uslan, and D. Pegues De novo daptomycin-nonsusceptible enterococcal infections Emerg Infect Dis 18 2012 674 676
56. L. Diaz, T.T. Tran, J.M. Munita, W.R. Miller, S. Rincon, and L.P. Carvajal Whole-genome analyses of Enterococcus faecium isolates with diverse daptomycin MICs Antimicrob Agents Chemother 58 2014 4527 4534
57. C.A. Arias, D. Panesso, D.M. McGrath, X. Qin, M.F. Mojica, and C. Miller Genetic basis for in vivo daptomycin resistance in enterococci N Engl J Med 365 2011 892 900
58. J.M. Munita, D. Panesso, L. Diaz, T.T. Tran, J. Reyes, and A. Wanger Correlation between mutations in liaFSR of Enterococcus faecium and MIC of daptomycin: revisiting daptomycin breakpoints Antimicrob Agents Chemother 56 2012 4354 4359
59. J.M. Munita, T.T. Tran, L. Diaz, D. Panesso, J. Reyes, and B.E. Murray A liaF codon deletion abolishes daptomycin bactericidal activity against vancomycin-resistant Enterococcus faecalis Antimicrob Agents Chemother 57 2013 2831 2833
60. A.C. Schutt, and N.M. Bohm Multidrug-resistant Enterococcus faecium endocarditis treated with combination tigecycline and high-dose daptomycin Ann Pharmacother 43 2009 2108 2112
61. I. Jenkins Linezolid- and vancomycin-resistant Enterococcus faecium endocarditis: successful treatment with tigecycline and daptomycin J Hosp Med 2 2007 343 344
62. C.A. Arias, H.A. Torres, K.V. Singh, D. Panesso, J. Moore, and A. Wanger Failure of daptomycin monotherapy for endocarditis caused by an Enterococcus faecium strain with vancomycin-resistant and vancomycin-susceptible subpopulations and evidence of in vivo loss of the vanA gene cluster Clin Infect Dis 45 2007 1343 1346
63. D.A. Enoch, N. Phillimore, J.A. Karas, L. Horswill, and D.A. Mlangeni Relapse of enterococcal prosthetic valve endocarditis with aortic root abscess following treatment with daptomycin in a patient not fit for surgery J Med Microbiol 59 2010 482 485
64. J.M. Munita, N.N. Mishra, D. Alvarez, T.T. Tran, L. Diaz, and D. Panesso Failure of high-dose daptomycin for bacteremia caused by daptomycin-susceptible Enterococcus faecium harboring LiaSR substitutions Clin Infect Dis 2014 10.1093/cid/ciu642 [pii: ciu642, Epub ahead of print, PMID: 25107294]
65. G. Sakoulas, A.S. Bayer, J. Pogliano, B.T. Tsuji, S.J. Yang, and N.N. Mishra Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium Antimicrob Agents Chemother 56 2012 838 844
66. B.S. Schwartz, P.D. Ngo, and B.J. Guglielmo Daptomycin treatment failure for vancomycin-resistant Enterococcus faecium infective endocarditis: impact of protein binding? Ann Pharmacother 42 2008 289 290
67. A. Hall Snyder, B.J. Werth, K.E. Barber, G. Sakoulas, and M.J. Rybak Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model J Antimicrob Chemother 69 2014 2148 2154
68. R. Kullar, S.L. Davis, D.P. Levine, J.J. Zhao, C.W. Crank, and J. Segreti High-dose daptomycin for treatment of complicated Gram-positive infections: a large, multicenter, retrospective study Pharmacotherapy 31 2011 527 536
69. E.A. King, D. McCoy, S. Desai, T. Nyirenda, and K. Bicking Vancomycin-resistant enterococcal bacteraemia and daptomycin: are higher doses necessary? J Antimicrob Chemother 66 2011 2112 2118
70. A.M. Casapao, R. Kullar, S.L. Davis, D.P. Levine, J.J. Zhao, and B.A. Potoski Multicenter study of high-dose daptomycin for treatment of enterococcal infections Antimicrob Agents Chemother 57 2013 4190 4196
71. J.M. Entenza, M. Giddey, J. Vouillamoz, and P. Moreillon In vitro prevention of the emergence of daptomycin resistance in Staphylococcus aureus and enterococci following combination with amoxicillin/clavulanic acid or ampicillin Int J Antimicrob Agents 35 2010 451 456
72. G. Sakoulas, W. Rose, P. Nonejuie, J. Olson, J. Pogliano, and R. Humphries Ceftaroline restores daptomycin activity against daptomycin-nonsusceptible vancomycin-resistant Enterococcus faecium Antimicrob Agents Chemother 58 2014 1494 1500
73. M. Sierra-Hoffman, O. Iznaola, M. Goodwin, and J. Mohr Combination therapy with ampicillin and daptomycin for treatment of Enterococcus faecalis endocarditis Antimicrob Agents Chemother 56 2012 6064
74. C.A. Beneri, D.P. Nicolau, H.S. Seiden, and L.G. Rubin Successful treatment of a neonate with persistent vancomycin-resistant enterococcal bacteremia with a daptomycin-containing regimen Infect Drug Resist 1 2008 9 11
75. M.P. Stevens, and M.B. Edmond Endocarditis due to vancomycin-resistant enterococci: case report and review of the literature Clin Infect Dis 41 2005 1134 1142
76. M. Polidori, A. Nuccorini, C. Tascini, G. Gemignani, R. Iapoce, and A. Leonildi Vancomycin-resistant Enterococcus faecium (VRE) bacteremia in infective endocarditis successfully treated with combination daptomycin and tigecycline J Chemother 23 2011 240 241